Reference for NIRSEVIMAB. Search for NIRSEVIMAB

AI searches containing NIRSEVIMAB

NIRSEVIMAB

Nirsevimab

Monoclonal antibody used as vaccine against RSV

Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It

Nirsevimab

Respiratory syncytial virus

Species of virus

GSK plc) and Abrysvo (Pfizer). The prophylactic use of palivizumab or nirsevimab (both are monoclonal antibody treatments) can prevent RSV infection among

Respiratory syncytial virus

Respiratory_syncytial_virus

Amsterdam University Medical Center

Hospital in Amsterdam, The Netherlands

has also laid the groundwork for multiple patented therapies, including Nirsevimab, originally discovered by cell biologist Hergen Spits. Amsterdam UMC's

Amsterdam University Medical Center

Amsterdam_University_Medical_Center

Respiratory syncytial virus F protein

development of vaccines and antiviral therapies against RSV infections. Nirsevimab, an approved medication, whole human monoclonal antibody against F protein

Respiratory syncytial virus F protein

Respiratory_syncytial_virus_F_protein

Bronchiolitis

Inflammation of the small airways in the lungs

them due to the clear benefit that they have shown in clinical trials. Nirsevimab, a monoclonal antibody against RSV, is approved by the FDA for all children

Bronchiolitis

MedImmune

Biopharmaceutical company, acquired by AstraZeneca in 2007

benralizumab (anti-IL-5R) tralokinumab (anti-IL-13) anifrolumab (anti-IFN-aR) nirsevimab (anti-RSV) MedImmune, Inc. v. Genentech, Inc. "12 years on, Astra draws

MedImmune

2023 in the United States

Stadium in Inglewood, California. July 17 – The FDA approves the drug Nirsevimab, also known as Beyfortus, which treats RSV in infants. July 18 – Michigan

2023 in the United States

2023_in_the_United_States

ZMapp

Experimental treatment for Ebola virus disease

Exbivirumab§ Foravirumab§ Imdevimab† (+casirivimab) Libivirumab§ Maftivimab Nirsevimab† Odesivimab Pemivibart Rafivirumab§ Regavirumab§ Regdanvimab Sevirumab†

ZMapp

List of therapeutic monoclonal antibodies

crystallizable receptor Y generalized myasthenia gravis, Sjögren's disease Nirsevimab Beyfortus mab human RSV fusion glycoprotein respiratory syncytial virus

List of therapeutic monoclonal antibodies

List_of_therapeutic_monoclonal_antibodies

ATC code J06

Pharmaceutical drug classification

Sotrovimab J06BD06 Regdanvimab J06BD07 Casirivimab and imdevimab J06BD08 Nirsevimab J06BD09 Sipavibart J06BD10 Clesrovimab J06BD11 Libevitug Immune sera and

ATC code J06

ATC_code_J06

Immunization during pregnancy

those under 180 days. Alternatively, a long-acting monoclonal antibody (nirsevimab or clesrovimab) may be administered shortly before or after birth in the

Immunization during pregnancy